Blood · 2011 · 94 citations · 43 references
MedicinePharmacokineticsPharmacologyClinical PharmacologyPharmacogeneticsPharmacogenomicsAnticoagulation ManagementAntithrombotic TherapyClinical Implementation Of PharmacogeneticsDose OptimizationDose SelectionPersonalized Drug DosingDose Regimen SelectionIntravenous Loading DosesLoading Dose CalculationLoading Dose DesignLoading Dose SchedulingWarfarin Dose OptimizationWarfarin Pharmacogenetic Testing
Single-nucleotide polymorphisms in genes that affect warfarin metabolism (cytochrome P450 2C9 gene, CYP2C9) and response (vitamin K epoxide reductase complex 1 gene, VKORC1) have an important influence on warfarin therapy, particularly during initiation; however, there is a lack of consensus regarding the optimal pharmacogenetics-based initiation strategy. We conducted a prospective cohort study in which patients requiring warfarin therapy for atrial fibrillation or venous thromboembolism were initiated with a novel pharmacogenetics-initiation protocol (WRAPID, Warfarin Regimen using A Pharmacogenetics-guided Initiation Dosing) that incorporated loading and maintenance doses based on genetics, clinical variables, and response (n = 167, followed up for 90 days), to assess the influence of genetic variations on anticoagulation responses. Application of the WRAPID algorithm resulted in a negligible influence of genetic variation in VKORC1 or CYP2C9 on time to achievement of first therapeutic response (P = .52, P = .28) and risk of overanticoagulation (P = .64, P = .96). After adjustment for covariates, time to stable anticoagulation was not influenced by VKORC1 or CYP2C9 genotype. Importantly, time spent within or above the therapeutic range did not differ among VKORC1 and CYP2C9 genotype groups. Moreover, the overall time course of the anticoagulation response among the genotype groups was similar and predictable. We demonstrate the clinical utility of genetics-guided warfarin initiation with the WRAPID protocol to provide safe and optimal anticoagulation therapy for patients with atrial fibrillation or venous thromboembolism.
43
Pharmacology and Management of the Vitamin K Antagonists
Jack Ansell, Jack Hirsh, Elaine M. Hylek et al. · CHEST Journal · 2008 · 2.1K citations
A Method to Determine the Optimal Intensity of Oral Anticoagulant Therapy
F.R. Rosendaal, Suzanne C. Cannegieter, F.J.M. van der Meer et al. · Thrombosis and Haemostasis · 1993 · 2.1K citations · Full text
Effect of <i>VKORC1</i> Haplotypes on Transcriptional Regulation and Warfarin Dose
Mark J. Rieder, Alex P. Reiner, Brian F. Gage et al. · New England Journal of Medicine · 2005 · 1.4K citations · Full text
Mutations in VKORC1 cause warfarin resistance and multiple coagulation factor deficiency type 2
Simone Rost, Andreas Fregin, Vytautas Ivaškevičius et al. · Nature · 2004 · 1.1K citations